Analysis of the polycythemia vera onset mechanism by investigating STAT5-target genes

2012 Fiscal Year Final Research Report

• Project/Area Number: 23790096
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Biological pharmacy
• Research Institution: Keio University
• Principal Investigator: TAGO Megumi 慶應義塾大学, 薬学部, 講師 (30445192)
• Project Period (FY): 2011 – 2012
• Keywords: JAK2 / V617F 点変異 / 真性赤血球増加症 / STAT5 / c-Myc / ODC / Aurka

Research Abstract

A point mutant of a tyrosine kinase JAK2 (V617F), which is a cause gene of polycythemia vera, induces cell proliferation and tumorigenesis through activation of a transcription factor STAT5. In this study , we found that a transcription factor

Research Products

• [Journal Article] Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasmassociated JAK2 V617F mutant (2013)
  • Author(s): Funakoshi-Tago M, Sumi K, Kasahara T, Tago K
  • Journal Title: PLoS One Volume: 8(1) Pages: e52844
  • DOI: doi:10.1371/journal.pone.005284
  • Peer Reviewed
• [Journal Article] Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasmassociated Janus kinase 2 (JAK2) V617F mutant (2013)
  • Author(s): Funakoshi-Tago M
  • Journal Title: Yakugaku Zasshi Volume: 132(11) Pages: 1267-1272
  • Peer Reviewed
• [Journal Article] Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway (2012)
  • Author(s): Funakoshi-Tago M, Nagata T, Tago K, Tsukada M, Tanaka K, Nakamura S, Mashino T, Kasahara T
  • Journal Title: Cell Signal Volume: 24(11) Pages: 2024-2034
  • DOI: doi:10.1016/j.cellsig.2012.06.014
  • Peer Reviewed
• [Journal Article] Analysis of the mechanism of polycythemia vera by studying JAK2 mutant-induced signaling pathway (2011)
  • Author(s): Funakoshi-Tago M
  • Journal Title: Yakugaku Zasshi Volume: 131(8) Pages: 1183-1187
  • Peer Reviewed
• [Journal Article] Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells (2011)
  • Author(s): Sumi K, Tago K, Kasahara T, Funakoshi-Tago M
  • Journal Title: FEBS Lett Volume: 585(12) Pages: 1884-1890
  • DOI: doi:10.1016/j.febslet.2011.04.068
  • Peer Reviewed
• [Journal Article] Anti-inflammatory activity of structurally related flavonoids, Apigenin, Luteolin and Fisetin (2011)
  • Author(s): Funakoshi-Tago M, Nakamura K, Tago K, Mashino T, Kasahara T
  • Journal Title: Int Immunopharmacol Volume: 11(9) Pages: 1150-1159
  • DOI: doi:10.1016/j.intimp.2011.03.012
  • Peer Reviewed
• [Journal Article] Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellulartransformation (2011)
  • Author(s): Kamishimoto J, Tago K, Kasahara T, Funakoshi-Tago M.
  • Journal Title: Cell Signal Volume: 23(5) Pages: 849-856
  • DOI: doi:10.1016/j.cellsig.2011.01.009
  • Peer Reviewed
• [Presentation] Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells (2012)
  • Author(s): Megumi Funakoshi-Tago
  • Organizer: the 37th FEBS/22nd IUBMB Congress
  • Place of Presentation: Seville, Spain
  • Year and Date: 2012-07-30
• [Presentation] 慢性骨髄増殖性腫瘍の原因遺伝子 JAK2V617F 変異体の癌化シグナルの解析 (2011)
  • Author(s): 多胡めぐみ
  • Organizer: 日本薬学会
  • Year and Date: 2011-03-30